General Information of Drug (ID: DMDNHRA)

Drug Name
Ilodecakin Drug Info
Synonyms Prevascar; Ilodecakin, Renovo; Recombinant IL-10 (scarring), Renovo
Indication
Disease Entry ICD 11 Status REF
Sarcoidosis 4B20.5 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDNHRA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Interleukin-10 (IL10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AM0010 DMGMNUE Pancreatic cancer 2C10 Phase 3 [3]
F-8-IL-10 fusion protein DMBFPO1 Endometriosis GA10 Phase 2 [4]
XT-150 DMCYM9Q Knee osteoarthritis FA01 Phase 2 [5]
AG019 DMEN2L7 Type-1 diabetes 5A10 Phase 1/2 [6]
Ankinara DMZKC7S Inflammatory bowel disease DD72 Investigative [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00984646) Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10). U.S. National Institutes of Health.
2 Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
3 Clinical pipeline report, company report or official report of ARMO BioSciences.
4 Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
5 Clinical pipeline report, company report or official report of Xalud Therapeutics
6 ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
7 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.